bpc 157 peptides capsules BPC-157 – Research Peptide BPC-157 Capsules – Nordsci

doi:10.1142/s0192415x98000415 Hijikata Y, Yamada S, Yasuhara A

ARE THERE ANY RISK FACTORS FOR DEVELOPING A B12 DEFICIENCY

Never freeze the reconstituted solution, protect it from light, and discard if it turns cloudy or shows particles

Initial treatment for patients with neurological involvement follows British National Formulary (BNF) guidance: Hydroxocobalamin 1 mg intramuscularly on alternate days for approximately 2-3 weeks (or until no further improvement) Maintenance therapy then consists of hydroxocobalamin 1 mg intramuscularly every two months Hydroxocobalamin is preferred over cyanocobalamin in the UK due to superior retention and fewer injections required

This is because hypokalemia and thrombocytosis could occur due to the increase in erythrocyte metabolism following vitamin B12 therapy

A course of two at 90 spaced two to four weeks apart is a common starter for patients with a more depleted baseline, working out to 45 per session